首页> 外文期刊>Applied health economics and health policy >Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System
【24h】

Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System

机译:替代定价基准在加州工人薪酬制度中替代定价基准的财务影响

获取原文
获取原文并翻译 | 示例
           

摘要

Background Pricing drugs in the California Workers' Compensation System (CAWCS) has become more difficult as there are increasingly fewer drugs listed in the Medi-Cal primary fee schedule, which is used as the source for CAWCS drug prices. This presents a challenge of providing timely and accurate CAWCS reimbursement. The objectives of this study are (1) to explore any trends in physician-dispensed drug prices; (2) to compare the proportion of drugs with and without a price and to determine the financial implications of repricing CAWCS physician-dispensed drugs with five alternative pricing benchmarks; and (3) to offer recommendations for the pricing benchmark to maximize pricing coverage and to remain budget neutral. Methods We evaluated physician-dispensed drugs at the transaction level, reimbursed in the CAWCS. Frequency, reimbursement rate, and total and average paid costs were reported. We matched each claim line in the CAWCS to the corresponding unit price of an alternative price benchmark including average wholesale price, wholesale acquisition cost, direct prices, national average drug acquisition cost, and Federal Upper Limit. Results Average wholesale price provided prices for 99.9% of physician-dispensed drug claims, while Medi-Cal, the current primary physician-dispensed drug benchmark provided prices for a lower percentage (92.7%) of claims. The CAWCS prices were equivalent to 49% of the average wholesale price, 95.5% of Medi-Cal, 126.7% of the wholesale acquisition cost, 266% of the Federal Upper Limit, 64.4% of direct prices, and 197% of national average drug acquisition cost-estimated prices. Conclusions The CAWCS current Medi-Cal pricing for physician-dispensed drugs is better than all alternatives in terms of price availability, transparency, and budget neutrality, but pricing availability may decrease over time as Medi-Cal moves to managed care. National average drug acquisition cost is the next best alternative, but it requires combinations of pricing benchmarks to maximize its price availability.
机译:背景技术加州工人赔偿系统(CAWCS)的定价毒品变得更加困难,因为Medi-Cal主要费表中列出的药物越来越少,被用作CAWCS药物价格的来源。这呈现了提供及时和准确的CAWCS报销的挑战。本研究的目标是(1)探讨医生分配药品价格的任何趋势; (2)比较毒品比例,无需价格,并确定具有五项替代定价基准的CAWCS医师分配药物的财务影响; (3)为定价基准提出建议,以最大限度地提高定价覆盖范围,并保持预算中性。方法我们在交易水平评估了医生分配的药物,在CAWCS中报销。报告了频率,报销率和总额和平均支付费用。我们将CAWC中的每个索赔行与相应的单位价格相媲美替代价格基准,包括平均批发价,批发收购成本,直接价格,国家平均药物收购成本和联邦上限。结果平均批发价格为99.9%的医生分配药物索赔,当时Medi-Cal,目前的主要医师分配的药物基准标记为索赔较低的百分比(92.7%)。 CAWCS价格相当于平均批发价格的49%,95.5%的Medi-Cal,批发收购成本的126.7%,占联邦上限的266%,占直接价格的64.4%,197%的国家平均药物收购成本估计价格。结论CAWCS当前医生分配药物的Medi-Cal定价优于价格可用性,透明度和预算中立方面的所有替代品,但随着Medi-Cal移动到管理护理,价格随着时间的推移可能会降低。国家平均药物收购成本是下一个最佳替代品,但需要定价基准组合来最大限度地提高其价格可用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号